Mizuho Reiterates Buy on Iovance Biotherapeutics, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Mara Goldstein has reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $30 price target.
June 27, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Mara Goldstein reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $30 price target.
The Buy rating and maintained $30 price target by Mizuho analyst Mara Goldstein on Iovance Biotherapeutics (NASDAQ:IOVA) indicates a positive outlook for the stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100